CD274 and non-small cell lung carcinoma: Data regarding safety of single-agent anti-PD1/PD-L1 in recurrent OC mirror those of melanoma and NSCLC trials, confirming the overall good tolerability of treatment and the low rate of severe (i.e., grade 3 according to CTCAE v 4.0) treatment-related adverse events AEs (~10–15%) [81,82,83,84,85,86,87,88,89,90,91,92].